Partner’s Institutions

Partners-Institutions

Vrije Universiteit Brussel (VUB)

The Vrije Universiteit Brussel is the offshoot of the French-speaking Université Libre de Bruxelles (ULB) that was founded in 1834 by a Brussels lawyer with Flemish origins, Pierre-Théodore Verhaegen. He wanted to establish a university that would be independent from the state and the church and where academic freedom would reign. The Vrije Universiteit Brussel is a dynamic and modern university with two parkland campuses in the Brussels Capital Region. VUB offers high quality education to more than 9000 students. Research teams are internationally recognised in many disciplines of fundamental and applied research. Over more than 150 research teams are performing high level research in different domains, including 1883 researchers and 1128 PhD students. The Laboratory Hematology and Immunology is part of the Myeloma Center Brussels and is incorporated in the Oncological Centre of the University Hospital and Faculty of Medicine. The facility includes a full cell culture unit, molecular biology unit with a 7900HT Fast Real-time PCR system, FACS sorter (BD FACSAria), FACS analyzer (BD FACSCanto, BD LSRFortessa), multiphoton microscope, transmission electron microscope, fluorescent microscopes, a dedicated space in the animal facility.

Principal investigator: Karin VANDERKERKEN


 

Partners-Institutions2
Institut National de la Santé et de la Recherche Médicale
(INSERM)

INSERM is a public institution with a scientific and technical vocation, under the dual auspices of the Ministry of Health and the Ministry of Higher Education and Research. Its researchers are committed to studying all diseases, whether common or rare, through their research in the fields of biology, medicine, and public health. The INSERM unit 1040 at the University of Montpellier I is located in the Institute for Research in Biotherapy (IRB, http://irb.chu-montpellier.fr, director Pr. B. Klein). IRB gathers 130 people working in fundamental and translational research laboratories, around common technical platforms.

Principal investigator: Bernard KLEIN


 

 

Partners-Institutions3

Universitaetsklinikum Heidelberg (UKL HD)

Heidelberg University is the oldest university in Germany. The first medical lectures were held here in 1388. Today Heidelberg University Hospital is one of the largest and most prestigious medical centers in Germany and the whole of Europe. The reputation of Heidelberg as a medical center is based on excellent patient care, research and teaching: Modern buildings with state-of-the-art equipment enable very ill persons to receive medical care that meets the highest international standards. Progress and innovation are essential for promising medical treatment. Hundreds of doctors and scientists at Heidelberg University Hospital and its partner research institutes, such as the world-renowned German Cancer Research Center, pursue a common aim: the development of new forms of therapy and their quick implementation for the benefit of the patient. The Medical Faculty and Heidelberg University Hospital work as a team to train outstanding doctors and dentists. Numerous doctors complete their post-graduate specialist training at a university level.  Top-class care and attention to the patient have priority in nursing and other health profession programs. The high standard of training for junior employees and ongoing staff development are reflected in excellent patient care.

Principal investigator : Dirk HOSE

 



Partners-Institutions4

University of Southampton (SOUTHAMPTON)

The University of Southampton combines academic excellence with an innovative and entrepreneurial approach to research, supporting a culture that engages and challenges students and staff in their pursuit of learning. Southampton’s record for success in spinning out its research excellence into business ventures has made it one of the leading entrepreneurial universities in the UK. As part of our drive to attract the most promising students, promote our groundbreaking research and forge new links with business and industry, we have developed close relationships with talented people and likeminded organisations across the world. Partner 4 is based in the Cancer Sciences Division (CSD) in The Faculty of Medicine, which in the 2008 UK Research Assessment Exercise (RAE) was ranked 4th for proportion of world-leading or internationally excellent research. The CSD has focused investigations on haematological malignancy, defining pathogenesis, molecular progression and novel targeted immunotherapies.

Principal investigator : Surinder SAHOTA



 

Partners-Institutions5

 

Academisch Medisch Centrum bij de Universiteit van Amsterdam (AMC)

The Academic Medical Center (AMC) is the most prominent medical center in the Netherlands and one of the largest hospitals. The Academic Medical Center (AMC) is one of the foremost research institutions in the Netherlands, as well as one of its largest hospitals. Over 7000 people work here to provide integrated patient care, fundamental and clinical scientific research, and teaching. The AMC complex houses the university hospital and the medical faculty of the University of Amsterdam, as well the Emma Children’s Hospital, the Netherlands Institute for Neuroscience and the medical department of the Royal Tropical Institute. Also a number of biotech companies partly AMC spin-offs - are located on the premises. This concentration of expertise makes the AMC more than just a university hospital and provides a breeding ground for fruitful scientific collaboration.

Principal investigator : Stevens T PALS

 


 

 

Partners-Institutions6


The Garvan Institute of Medical Research
(GIMR)


Garvan has grown to become one of Australia's largest autonomous medical research institutions with over four hundred scientists, students and support staff. Garvan enjoys major collaborative programs with national and international institutions and places emphasis on establishing links with hospitals and industry. The Garvan Institute of Medical Research is a world leader in biomedical research, pioneering study into some of the most widespread diseases affecting our community today. Research at Garvan is focused on understanding the role of genes and molecular and cellular processes in health and disease as the basis for developing future cures. For over 45 years, significant breakthroughs have been achieved by Garvan scientists in the understanding and treatment of diseases such as:  Cancer, Diabetes and obesity, Alzheimer’s and Parkinson’s disease, Osteoporosis, Arthritis, asthma, rheumatoid arthritis and other immune disorders, Pituitary disorders. Garvan’s ultimate goal is prevention and cure of these major diseases.


Principal investigator : Peter CROUCHER

 


 


Partners-Institutions7


Universita Degli Studi di Bari "ALDO MORO" (UNIBA)


The University of Bari “Aldo Moro,” whose main campus is located in the city of Bari, is an Italian public university founded in 1925. With over 60,000 students, it is the main university of Puglia, and one of the major Italian universities. The University comprises fifteen schools of studies, offering 150 Bachelor’s Degrees; it also houses many libraries and media centers supporting many inter-university projects. The University continuously provides multimedia classrooms, public displays, info points, and other instruments geared to increase the quality of teaching and to improve services and communications between students and the university.


Principal investigator : Angelo VACCA

 


 

ODS

 

ONCODESIGN (ODS)

 
Oncodesign® is a pioneer in the preclinical assessment of anti-cancer therapy, a market that it has led for many years now. The company's mission consists of discovering effective anti-cancer therapies. Its scientific expertise in pharmacology, imaging and medicinal chemistry, in addition to strong project management skills, supports the company’s two strategic activities of experimentation and discovery, conducted in partnership with pharmaceutical and biotechnology companies. Oncodesign® has incorporated a medicinal chemistry technology into its discovery activity: Nanocyclix®, which is dedicated to the synthesis and optimization of new compounds used for therapeutic and diagnostic purposes. This technology is currently applied to the synthesis of highly potent and specific novel kinase inhibitors. This medicinal chemistry platform provides access to biologically active macrocyclic small molecules with unique properties. The Nanocyclix® library contains hundreds of diversified and novel kinase inhibitors that provide highly potent and selective leads for both well established and unexplored kinases, with good overall drug-like properties. In addition, the platform approach allows for accelerated and resource-efficient optimisation.


Principal investigator : Jan Hoflack

 


 

 



Partners-Institutions9


Inserm-Transfert SA (IT)


Founded in 2001, Inserm-Transfert SA is the private subsidiary of the French Institute for Health and Medical Research (INSERM), dedicated to Technology Transfer and management of European and International collaborative research projects. The company possesses extensive expertise in two core areas: i) Intellectual Property management, Technology Transfer and exploitation of research results; ii) specific tools and gold standard methods for supporting scientists in their international project preparation and management. Over the last 8 years, the European and International departement of Inserm-Tansfert has managed more than 25 FP6 & 24 FP7 projects in the field of life sciences and health. The Department of EU Affairs has a strong expertise in the financial and contractual rules of the FP7 program and all related regulatory aspects linked to European cooperation. It can anticipate and solve quickly any kind of emerging problems within large consortia. The Department of EU Affairs is certified ISO 9001.2008 since January 2010 for the management of European and International biomedical research projects. The company has already established management links with almost all life science organisations, including more than 50 biotech SMEs, in Europe.


Principal investigator : Dahlia TSAKIROPOULOS

Overmyr © 2012